Glaukos reports stronger-than-expected Q2 earnings and revenue growth, raising 2026 net sales outlook to $680M-$700M.
Glaukos posted a Q2 non-GAAP loss per share of $0.14, beating estimates by $0.07, as revenue surged 49.6% year-over-year to $185.6 million. The top line also exceeded expectations by $34.69 million.
The company’s revenue growth reflects strong demand for its medical devices, outpacing prior-year performance. Analysts had anticipated a narrower loss and lower sales for the quarter.
Glaukos updated its 2026 net sales forecast to a range of $680 million to $700 million, based on current foreign exchange rates.